Substantial research has been implemented to delineate the efficacy, mechanism of action and identification of the medicinal components of natural extracts for clinical use, especially in the field of cancer. This project is aimed at identifying all biologically active components of dandelion root extract (DRE), a natural health product (NHP) that has shown potential as an anticancer agent. The identification of these components will enable the development of quality control standards for DRE.

Nethasol est une entreprise du secteur des nouvelles énergies et de l’environnement qui évolue au sein des entreprises agricoles. Cette dernière a mis au point une technologie de captation du sirop noir généré par les techniques traditionnelles d'ensilage en silo. Actuellement, tous les silos ont un drain permettant l’écoulement de ce déchets agricoles (sirop noir) vers les faussés de campagne. Or, grâce à la technologie et aux installations de Nethasol, il est possible de recueillir près le sirop noir pour une installation d’ensilage moyenne.

Hypercholesterolemia, characterized by increased plasma low-density lipoprotein cholesterol, is a major determinant of the risk of cardiovascular disease (the leading cause of global mortality). Unfortunately, the commonly known cholesterol-lowering drugs are not effective enough to obtain the recommended cholesterol levels for many people. PCSK9 plays a critical role in cholesterol metabolism, and thus its inhibition emerged as a novel therapeutic target for hypercholesterolemia.

Research into understanding and controlling microscopic quantum mechanical phenomena has led to revolutionary new quantum devices, including quantum sensors and actuators that have unprecedented levels of sensitivity, efficiency, and functionality for a wide variety of tasks. A particularly compelling example is high quality factor (high-Q) superconducting resonators for magnetic resonance. These new devices will be substantially more sensitive than current devices in widespread use.

This project aims to develop an aptamer-based technology to enhance the in-vivo survival of oncolytic viruses and thus the efficiency of virotherapy. Oncolytic viruses (OVs) can selectively replicate in tumor cells, leading to lysis of the tumor. OVs are particularly effective against metastatic cancers, which are especially difficult to treat conventionally. However, OVs can be deactivated by antiviral neutralizing antibodies (nAbs) and cleared from the circulation.

Ventures (IV)~ Canada supports the development of novel application for guided catheters and serving the CVD market, it will directly benefit from this research. We anticipate generating new intellectual properties based on the work described. N previously licensed a technology from the research performed in Kizhakkedathu and Phani's laboratories on catheters and the current project will expand that technology further.

The main cause of cardiovascular disease (CVD) is narrowing of blood vessels due to atherosclerosis. In such cases stents are chronically implanted in -arteries to physically expand and scaffold the vessels. Each year, ~90,OOO stents are implanted in Canadians. All these minimally invasive procedures involve the use of a catheter. Currently available catheter tubes advance straight in blood vessels; it remain a challenge to the cardiac catheterization in bifurcated cardiac arteries which are blocked.

Pour réussir à répondre aux questions qui se posent sur la nature et la présence des contaminants émergents (connus et inconnus) dans l’environnement, plusieurs objectifs seront nécessaires.

Ils seront

i) de cibler les familles de composés d’importance selon notre contexte en ce qui concerne l’industrie pharmaceutique, agroalimentaire et le domaine de la médecine vétérinaire;

ii) d’établir une liste de leurs produits de transformation/dégradation dans la l’environnement et leurs métabolites, selon la littérature, ou les travaux faits dans l’industrie pharmaceutique;

OBJECTIVE; We will advance our development of novel specific inhibitors of the retinoic acid (RA) metabolizing P450 enzymes, CYP26A1 and CYP26B1, to treat skin disorders - an approach that will have significant safety advantages over current retinoid therapies. These inhibitors will be used primarily to target cystic acne but will also be evaluated for their therapeutic potential in treating other skin disorders including actinic keratosis, rosacea, oral leukoplakia and skin cancer.

Research in the Barry lab has been following two independent streams of precursor development: NHC complexes of group 11 amides for the deposition of metal films, and development of designed iminopyrrolidinates to quench low temperature thermal decomposition mechanisms. A series of novel N-heterocyclic carbene (NHC)-containing copper(I) amides have been shown to be viable ALD precursors. This family is represented by the compounds 4,5-dimethyl-1,3-diisopropyl-imidazol-2-ylidene copper hexamethyldisilazide, which was synthesized and structurally characterized.